Marker Therapeutics (MRKR) has released an update.
Marker Therapeutics has reported promising preliminary results from the Phase 1 APOLLO study of MT-601, showing sustained objective responses in lymphoma patients without significant side effects. Additionally, the company has secured a $2 million NIH grant to further the clinical investigation of MT-601, highlighting its potential to meet an unmet medical need in non-Hodgkin’s lymphoma treatment.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
